[局限性前列腺癌的超分割放疗。HYPO-RT-PC试验的5年结果：评论I] - Suppr

[Ultra-hypofractionation in localized prostate cancer. 5-year results of the HYPO-RT-PC trial: Commentary I].

作者信息

Jiang Ping, Blanck Oliver, Dunst Jürgen

机构信息

Universitätsklinik für Medizinische Strahlenphysik, Medizinischer Campus Pius-Hospital, Carl von Ossietzky Universität Oldenburg, Oldenburg, Deutschland.

Klinik für Strahlentherapie, Christian-Albrechts-Universität zu Kiel & Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland.

出版信息

Strahlenther Onkol. 2019 Dec;195(12):1116-1118. doi: 10.1007/s00066-019-01535-5.

DOI:10.1007/s00066-019-01535-5

PMID:31667552

Abstract

摘要

相似文献

[Ultra-hypofractionation in localized prostate cancer. 5-year results of the HYPO-RT-PC trial: Commentary I].

Strahlenther Onkol. 2019 Dec;195(12):1116-1118. doi: 10.1007/s00066-019-01535-5.

[Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: HYPO-RT-PC randomized trial. 5-year results: Commentary II].

Strahlenther Onkol. 2019 Dec;195(12):1119-1121. doi: 10.1007/s00066-019-01536-4.

Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiothe-rapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Int Braz J Urol. 2020 Nov-Dec;46(6):1100-1101. doi: 10.1590/S1677-5538.IBJU.2020.06.09.

Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):823-833. doi: 10.1016/j.ijrobp.2018.11.020. Epub 2018 Nov 17.

Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis.

Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):735-744. doi: 10.1016/j.ijrobp.2019.07.027. Epub 2019 Aug 1.

Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study.

Radiat Oncol. 2019 Jan 30;14(1):23. doi: 10.1186/s13014-019-1223-2.

Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.

Cancer Commun (Lond). 2018 Apr 17;38(1):11. doi: 10.1186/s40880-018-0281-4.

[Effects of hypofractionated radiation therapy for men with localized prostate cancer].

Urologe A. 2020 Aug;59(8):953-956. doi: 10.1007/s00120-020-01262-1.

Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.

Anticancer Res. 2013 Oct;33(10):4537-43.

Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):871-873. doi: 10.1016/j.ijrobp.2017.12.274.

本文引用的文献

Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Radiother Oncol. 2019 Oct;139:83-86. doi: 10.1016/j.radonc.2019.07.018. Epub 2019 Aug 17.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.

Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.

Radiat Oncol. 2017 Aug 18;12(1):138. doi: 10.1186/s13014-017-0872-2.

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.

Radiother Oncol. 2017 Jul;124(1):56-60. doi: 10.1016/j.radonc.2017.06.014. Epub 2017 Jun 27.

Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.

J Clin Oncol. 2017 Jun 10;35(17):1891-1897. doi: 10.1200/JCO.2016.70.4189. Epub 2017 Mar 29.

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

J Clin Oncol. 2017 Jun 10;35(17):1884-1890. doi: 10.1200/JCO.2016.71.7397. Epub 2017 Mar 15.

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Ultra-hypofractionation in localized prostate cancer. 5-year results of the HYPO-RT-PC trial: Commentary I].

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献